Miltuximab

N/A

Report date: 2025/11/21 17:16:17

Base Information

Drug NameMiltuximab

Drug Alias Nameanti-GPC-1 monoclonal antibody (minomic)MILGaMIL-38/Gallium67

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyRadiation-emitting products > Nuclides > Gallium > 67GaRadiation-emitting products > Radionuclide Drug Conjugates +[5]

Mechanisms of ActionSingle-photon emission-computed tomography enhancersGlypican-1 antagonistsWnt signalling pathway inhibitors

TargetsGlypican-1

Therapy Area/IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesGlytherix

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsUrinary Bladder NeoplasmsProstatic NeoplasmsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A